BD Expects Edwards Lifesciences' Critical Care Transaction To Be Immediately Accretive To All Key Financial Measures
Portfolio Pulse from Benzinga Newsdesk
BD (Becton, Dickinson and Company) expects its acquisition of Edwards Lifesciences' Critical Care business to be immediately accretive to all key financial measures. The deal, valued at approximately $4.2 billion, will be funded with $1 billion in cash and $3.2 billion in new debt.
June 03, 2024 | 10:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BD's acquisition of Edwards Lifesciences' Critical Care business is expected to be immediately accretive to all key financial measures, including revenue growth, margins, and earnings per share.
The acquisition is expected to enhance BD's financial performance immediately, positively impacting revenue growth, margins, and earnings per share. The market is likely to react positively to this news.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Edwards Lifesciences is selling its Critical Care business to BD for $4.2 billion. This divestiture could allow Edwards to focus on its core operations and potentially improve its financial health.
The sale of the Critical Care business will provide Edwards Lifesciences with significant capital, which could be used to strengthen its core operations and improve financial health. The market may view this divestiture positively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100